NCT00788060View on ClinicalTrials.gov

A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma

PHASE1CompletedINTERVENTIONAL

Enrollment

5

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions

Renal Cell Carcinoma

Interventions

DRUG

Everolimus (RAD001)

5mg per day, continuously

DRUG

Sunitinib (Sutent)

37.5 mg per day, 14 days on, 7 day break

Trial Locations (1)

27705

Duke University Medical Center, Durham

Sponsors

Collaborators (2)

All Listed Sponsors

collaborator

Novartis

INDUSTRY

collaborator

Pfizer

INDUSTRY

lead

Daniel George, MD

OTHER